In Lilly's 2026 TRIUMPH-1 Phase 3 readout, the primary body-weight endpoint was measured at 80 weeks, with extension data running to 104 weeks
However, maximal glucose-lowering effects generally occur after 45 weeks at a stable dose, once steady-state drug levels are achieved
They also tended toward higher oxygen consumption
The Outcome Reduction with Initial Glargine Intervention trial (i.e., ORIGIN) was an open-label, randomized, 12,537 patient study that compared LANTUS to standard care on the time to first occurrence of a major adverse cardiovascular event (MACE)
The systematic search methodology and eligibility criteria for study selection are presented in Table 1
Oral GLP-1 Formulations and Future Projections Several companies are developing oral GLP-1 formulations, including Novo Nordisk, Pfizer, and smaller firms, positioning them as potential acquisition targets